The overexpression of FGFR4 in breast cancer, which is instrumental in tumor progression, metastasis, and endocrine resistance, could potentially serve as a compelling target for therapeutic intervention [21, 22]. This evidence concerns the gene FGFR4 and breast carcinoma.